BioRestorative Therapies, Inc. (BRTX) - Dilution Analysis

10-Q filing | 25.5M shares outstanding

10-K filing | 25.5M shares outstanding

10-Q filing | 9.1M shares outstanding

8-K filing: BioRestorative Therapies, Inc. entered into subscription agreements to sell 678,125 shares of common stock at $1.60 per share and agreed to issue warrants to purchase up to 508,592 shares at $2.75 per share in a concurrent private placement. ($1.09M proceeds)

10-Q filing | 7.5M shares outstanding

10-K filing | 7.8M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.7M shares outstanding

S-1 filing: Registration statement for the offer and sale of up to 2,513,686 shares of common stock by selling securityholders.

10-K filing | 6.8M shares outstanding

8-K filing: BioRestorative Therapies, Inc. entered into agreements with warrant holders to exercise their existing warrants for 3,351,580 shares at a reduced price of $2.33 per share, in exchange for new warrants, resulting in gross proceeds of approximately $8.1 million. ($8.1M proceeds)

10-Q filing | 4.6M shares outstanding

10-Q filing | 4.7M shares outstanding

8-K filing: BioRestorative Therapies, Inc. entered into a securities purchase agreement to sell 685,033 shares of common stock at $3.03 per share in a registered direct offering, with gross proceeds of approximately $2.1 million, intending to use the net proceeds for clinical trials, research and development, and general corporate purposes. ($2.1M proceeds)

10-Q filing | 3.7M shares outstanding

10-K filing | 3.6M shares outstanding

S-3 filing: BioRestorative Therapies, Inc. files an S-3 form to offer common stock, preferred stock, and debt securities up to an aggregate amount of $75,000,000.

10-Q filing | 3.6M shares outstanding

POS AM filing: This POS AM filing from BioRestorative Therapies, Inc. relates to shares of common stock issuable upon the exercise of outstanding Public Warrants and Representative Warrants, with the net proceeds intended for clinical trials, research and development, and general corporate purposes.

8-K filing: BioRestorative Therapies, Inc. issued 1,543,158 shares of Series B preferred stock to Auctus Fund, LLC in exchange for an equal number of shares of the Company's outstanding Series A preferred stock.

POS AM filing: This is a POS AM filing for BioRestorative Therapies, Inc. regarding the offering of common stock issuable upon the exercise of outstanding Public Warrants and Representative Warrants.

10-Q filing | 3.6M shares outstanding

S-3 filing: This S-3 filing registers 1,856,938 shares of common stock for sale by selling securityholders. The company will not receive any proceeds from the sale of these shares.

10-Q filing | 3.5M shares outstanding

10-K filing | 3.6M shares outstanding

RW filing: This is an RW filing to withdraw the S-1 Registration Statement with file number 333-231079, which was for the registration of Company common stock and warrants.

10-Q filing | 3.5M shares outstanding

8-K filing: BioRestorative Therapies, Inc. issued 313,780 shares of common stock, 1,543,158 shares of Series A preferred stock and warrants for 1,856,938 shares of common stock in exchange for convertible promissory notes in the aggregate principal amount of $10,046,897, together with accrued interest thereon, and warrants for 3,677,997 shares of common stock valued at $7,846,774. ($7.85M proceeds)

8-K filing: BioRestorative Therapies, Inc. entered into an underwriting agreement to sell 2,300,000 units, each consisting of one share of common stock and one warrant, at a price of $10.00 per Unit, with the offering expected to close on November 9, 2021, and the underwriters exercising their over-allotment option as to the Warrants for the purchase of 345,000 shares of Common Stock, resulting in net proceeds of approximately $20,869,000 for general corporate purposes and clinical trials. ($23.0M proceeds)

S-1/A filing: S-1/A filing on 2021-10-29 regarding the offering price and exercise price of units, considering market conditions, historical performance, business potential, and management assessment.

8-K filing: Stock split 1-for-4000 | Outstanding: 3,350,844,445 → 837,711

8-K filing: BioRestorative Therapies, Inc. entered into Exchange Agreements with Auctus Fund, LLC and three other holders of convertible promissory notes and warrants for units of common stock and warrants in a contemplated public offering.

S-1/A filing: The filing is an S-1/A amendment. The offering price and exercise price for the warrants were negotiated between the underwriters and the company.

10-Q filing | 3350.8M shares outstanding

10-Q filing | 3176.0M shares outstanding

10-K filing | 77.9M shares outstanding

10-Q filing | 77.9M shares outstanding

10-Q filing | 77.9M shares outstanding

10-Q filing | 77.9M shares outstanding

10-K filing | 11.7M shares outstanding

8-K filing: BioRestorative Therapies, Inc. issued 98,952,799 shares of common stock upon the exercise of conversion rights by holders of convertible promissory notes for $98,953. Following the issuance, there were approximately 1,793,503,850 shares of common stock outstanding. ($0.1M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 366,721,142 shares of common stock upon conversion of debt totaling $366,721, resulting in approximately 1,694,551,051 shares outstanding. ($0.37M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 327,123,339 shares of common stock upon the exercise of conversion rights by holders of convertible promissory notes between February 11, 2020 and February 20, 2020, resulting in approximately 1,328,000,000 shares outstanding. ($0.33M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 86,284,252 shares of common stock upon the exercise of conversion rights by holders of convertible promissory notes for $86,284. ($0.09M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 390,199,220 shares of common stock upon the exercise of conversion rights by holders of convertible promissory notes in the aggregate amount of $390,199 between February 3, 2020 and February 7, 2020. ($0.39M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 201,436,602 shares of common stock upon the exercise of conversion rights by holders of outstanding indebtedness in the amount of $205,166 between January 27, 2020 and January 31, 2020. ($0.21M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 139,505,847 shares of common stock in exchange for $198,833 of outstanding indebtedness between January 17, 2020 and January 24, 2020. ($0.2M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 71,247,641 shares of common stock in exchange for $186,914 of outstanding indebtedness, issued 1,000,000 shares of common stock and a warrant to purchase 1,000,000 shares for $10,000, and issued a convertible promissory note for $85,000. ($0.02M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 37,553,208 shares of common stock in exchange for $112,271 of outstanding indebtedness between January 8, 2020 and January 10, 2020. ($0.11M proceeds)

8-K filing: BioRestorative Therapies, Inc. issued 56,225,589 shares of common stock in exchange for $158,192 of outstanding indebtedness between December 26, 2019 and January 7, 2020. ($0.16M proceeds)